Angiotech Pharmaceuticals, (NASDAQ: ANPI, TSX: ANP) will host a conference call discussing its financial results for the third quarter ended September 30, 2009, on Monday November 9, 2009 at 11:00 AM ET (8:00 AM Pacific).Dial-in information for the earnings call on November 9, 2009 is as North America (toll-free): 800.599.9829;International: 617.847.8703; Enter Passcode: 64385781
Best Damn Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Stock Newsletter
A live webcast of the earnings call will be available to interested parties through Angiotech's website at in the Investor Relations section. A press release announcing Angiotech's financial results will be issued prior to the call on November 9, 2009 at approximately 8:00 AM ET (5:00 AM Pacific).An archived replay of the call will be available until November 16, 2009.Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with over 1,300 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech (NASDAQ: ANPI, TSX: ANP). Angiotech Pharmaceutical is redefining success by striving to create novel medical solutions that elevate the standard of care and improve people's lives.its corporate partner, Boston Scientific Corporation (NYSE: BSX), has released comprehensive data from the TAXUS ATLAS clinical program, a series of global prospective, single-arm trials evaluating the TAXUS® Liberté ® Paclitaxel-Eluting Stent System in a variety of lesions and patient groups. Three-year results from the TAXUS ATLAS Small Vessel and Long Lesion Trials continue to show significant advantages for the newer TAXUS Liberté Stent when compared to the first-generation TAXUS® Express® Stent. The data were presented at the 21st annual Cardiovascular Research Foundation's (CRF) annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in San Francisco.
Sign up for the free Best Damn Penny Stocks newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website
About Best Damn Penny Stocks
Best Damn Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer
